About CHRI
CHRI aims to inform clinical decision-making, product development and public policy related to the therapeutic use of cannabinoids through objective documentation and analysis of firsthand experiences with medicinal cannabis.
The Purpose of CHRI
CHRI is intended to be a platform of data collection and dissemination focused on patient-level health outcomes related to the therapeutic use of cannabis and cannabis-derived products. The aim of CHRI is to help inform clinical decision-making, identify target areas for the development of cannabinoid therapeutics, and steer policy and regulatory decisions in the interest of public and patient health.
At its inception, CHRI will include a national patient research registry, a cannabis product surveillance and testing program, an integrated data and research tool repository for scientists, and a library of published research on the medicinal applications of cannabinoids. We will also begin developing natural language processing tools for conducting research on de-identified electronic medical records and validated research assessments.
Diversity, Equity and Inclusion
CHRI is committed to representing the history, research and future of cannabis responsibly, furthering our goals of challenging oppressive ideologies, policies and systems that impact families and communities, particularly those of color. Through research and education, we aim to promote a culture that destigmatizes and normalizes discussions surrounding cannabis use for medicinal purposes.
Our Programs
Data Repository
De-identified data collected through CHRI’s programs and similar projects.
Research Library
Published scientific articles related to the health effects of cannabis.
What is Cannabis?
“Cannabis” is a chemically complex genus of plants from which a variety of products intended for therapeutic or medicinal use are derived. Products referred to as cannabis, marijuana, hemp and cannabinoids are all included under this category and are of interest to CHRI.
CHRI aims to research the health impacts of products in which the main ingredients are naturally found in or sourced from the cannabis plant. This includes products intended to be inhaled, swallowed, topically applied or inserted. These products may be obtained from state-regulated cannabis dispensaries, other retail stores (such as CBD stores, health stores and “head shops”), online retailers and unregulated sources (like friends, neighbors and black market suppliers).
Note: This is not an exhaustive list of all cannabinoids.
- Δ9-Tetrahydrocannabinol (Δ9-THC)
- Δ8-Tetrahydrocannabinol (Δ8-THC)
- Δ9-Tetrahydrocannabivarin (THCV)
- Δ9-Tetrahydrocannabinolic acid (THCA)
- Δ10-Tetrahydrocannabinol (Δ10-THC)
- Cannabidiol (CBD)
- Cannabigerol (CBG)
- Cannabinol (CBN)
- Cannabichromene (CBC)
- Cannabivarin (CBV)
- Cannabidivarin (CBDV)
- Cannabinodiol (CBND)
- Cannabielsion (CBE)
- Cannabicyclol (CBL)
- Cannabitriol (CBT)
- Cannabigerovarin (CBGV)
- Cannabichromevarin (CBCV)
- Cannabidiolic acid (CBDA)
- Cannabigerolic acid (CBGA)
- Cannabichromenolic acid (CBCA)
- Cannabigerovarinic acid (CBGVA)
- Cannabichromevarinolic acid (CBCVA)
- Cannabidivarinolic acid (CBDVA)
- Tetrahydrocanabivarinic acid (THCVA)
- Flower
- Vape Cartridges
- Edibles including, but not limited to:
- Candy
- Chocolates
- Beverages
- Baked goods
- Cooking oils and sauces
- Savory snacks
- Lozenges
- Dissolvable powder
- Beverages
- Oils and Tinctures
- Pills and Capsules
- Suppositories
- Topicals including, but not limited to:
- Body oil
- Moisturizer
- Salves
- Lotions
- Balms
CHRI aims to inform clinical decision-making, product development and public policy related to the therapeutic use of cannabinoids.